Literature DB >> 7625464

Clinical aspects of chronic use of alprazolam and lorazepam.

M Romach1, U Busto, G Somer, H L Kaplan, E Sellers.   

Abstract

OBJECTIVE: The authors' goal was to determine the clinical characteristics of persistent users of alprazolam or lorazepam who wished to discontinue their medication.
METHOD: Long-term users (daily use for more than 3 months) of alprazolam (N = 34) or lorazepam (N = 97) who entered an outpatient treatment program for discontinuation of benzodiazepines were carefully assessed. Detailed histories of benzodiazepine use were obtained; a structured interview was used to make psychiatric diagnoses based on DSM-III-R criteria.
RESULTS: The majority of patients were using low therapeutic doses of medication (lorazepam: mean = 2.7 mg/day; alprazolam: mean = 1.2 mg/day) and had either maintained their initial daily dose over time or decreased it. Individuals tended to shift their use of medication from an as-prescribed to an as-needed pattern. Forty-seven percent of the patients were diagnosed with at least one current anxiety disorder, most commonly generalized anxiety. At least one diagnosable personality disorder was found in 45% of the patients, most commonly obsessive-compulsive personality disorder. Patterns of benzodiazepine use were influenced by age, gender, and past history of alcohol dependence.
CONCLUSIONS: Long-term users of alprazolam/lorazepam seeking treatment for discontinuation had clinically important past and current psychiatric histories. They used a constant or decreasing dose of medication and made attempts to stop their use. Persistent use of alprazolam/lorazepam for therapeutic purposes did not represent abuse or addiction as the terms are usually understood. A substantial proportion of these patients may be receiving appropriate maintenance therapy for a chronic psychiatric condition.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7625464     DOI: 10.1176/ajp.152.8.1161

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  8 in total

Review 1.  Separation of anxiety and depressive disorders: blind alley in psychopharmacology and classification of disease.

Authors:  Edward Shorter; Peter Tyrer
Journal:  BMJ       Date:  2003-07-19

2.  Initial benzodiazepine use and improved health-related quality of life.

Authors:  Rolf van Hulten; Bart Teeuw; Albert Bakker; Hubert G Leufkens
Journal:  Pharm World Sci       Date:  2005-02

3.  Usage patterns of benzodiazepines in a Dutch community: a 10-year follow-up.

Authors:  R van Hulten; H G Leufkens; A Bakker
Journal:  Pharm World Sci       Date:  1998-04

4.  Results of a naturalistic longitudinal study of benzodiazepine and SSRI use in the treatment of generalized anxiety disorder and social phobia.

Authors:  Russell G Vasile; Steven E Bruce; Robert M Goisman; Maria Pagano; Martin B Keller
Journal:  Depress Anxiety       Date:  2005       Impact factor: 6.505

5.  Non-medical use, abuse and dependence on sedatives and tranquilizers among U.S. adults: psychiatric and socio-demographic correlates.

Authors:  William C Becker; David A Fiellin; Rani A Desai
Journal:  Drug Alcohol Depend       Date:  2007-06-01       Impact factor: 4.492

6.  Mechanism of triazolo-benzodiazepine and benzodiazepine action in anxiety and depression: behavioral studies with concomitant in vivo CA1 hippocampal norepinephrine and serotonin release detection in the behaving animal.

Authors:  P A Broderick; O Hope; P Jeannot
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1998-02       Impact factor: 5.067

7.  Clonazepam as agonist substitution treatment for benzodiazepine dependence: a case report.

Authors:  Angelo Giovanni Icro Maremmani; Luca Rovai; Fabio Rugani; Silvia Bacciardi; Matteo Pacini; Liliana Dell'osso; Icro Maremmani
Journal:  Case Rep Psychiatry       Date:  2013-01-30

8.  Concomitant lorazepam use and antidepressive efficacy of repetitive transcranial magnetic stimulation in a naturalistic setting.

Authors:  M Deppe; M Abdelnaim; T Hebel; P M Kreuzer; T B Poeppl; B Langguth; M Schecklmann
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-07-09       Impact factor: 5.270

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.